Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Abstract:

:Breast cancers with BRCA1 germline mutation have a characteristic DNA copy number (CN) pattern. We developed a test that assigns CN profiles to be 'BRCA1-like' or 'non-BRCA1-like', which refers to resembling a BRCA1-mutated tumor or resembling a tumor without a BRCA1 mutation, respectively. Approximately one third of the BRCA1-like breast cancers have a BRCA1 mutation, one third has hypermethylation of the BRCA1 promoter and one third has an unknown reason for being BRCA1-like. This classification is indicative of patients' response to high dose alkylating and platinum containing chemotherapy regimens, which targets the inability of BRCA1 deficient cells to repair DNA double strand breaks. We investigated whether this classification can be reliably obtained with next generation sequencing and copy number platforms other than the bacterial artificial chromosome (BAC) array Comparative Genomic Hybridization (aCGH) on which it was originally developed. We investigated samples from 230 breast cancer patients for which a CN profile had been generated on two to five platforms, comprising low coverage CN sequencing, CN extraction from targeted sequencing panels (CopywriteR), Affymetrix SNP6.0, 135K/720K oligonucleotide aCGH, Affymetrix Oncoscan FFPE (MIP) technology, 3K BAC and 32K BAC aCGH. Pairwise comparison of genomic position-mapped profiles from the original aCGH platform and other platforms revealed concordance. For most cases, biological differences between samples exceeded the differences between platforms within one sample. We observed the same classification across different platforms in over 80% of the patients and kappa values of at least 0.36. Differential classification could be attributed to CN profiles that were not strongly associated to one class. In conclusion, we have shown that the genomic regions that define our BRCA1-like classifier are robustly measured by different CN profiling technologies, providing the possibility to retro- and prospectively investigate BRCA1-like classification across a wide range of CN platforms.

journal_name

Mol Oncol

journal_title

Molecular oncology

authors

Schouten PC,Grigoriadis A,Kuilman T,Mirza H,Watkins JA,Cooke SA,van Dyk E,Severson TM,Rueda OM,Hoogstraat M,Verhagen CV,Natrajan R,Chin SF,Lips EH,Kruizinga J,Velds A,Nieuwland M,Kerkhoven RM,Krijgsman O,Vens C,Pe

doi

10.1016/j.molonc.2015.03.002

subject

Has Abstract

pub_date

2015-08-01 00:00:00

pages

1274-86

issue

7

eissn

1574-7891

issn

1878-0261

pii

S1574-7891(15)00051-4

journal_volume

9

pub_type

杂志文章
  • Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.

    abstract::Thyroid transcription factor-1 (TTF-1, encoded by the NKX2-1 gene) is highly expressed in small-cell lung carcinoma (SCLC) and lung adenocarcinoma (LADC), but how its functional roles differ between SCLC and LADC remains to be elucidated. Here, we compared the genome-wide distributions of TTF-1 binding regions and the...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12608

    authors: Hokari S,Tamura Y,Kaneda A,Katsura A,Morikawa M,Murai F,Ehata S,Tsutsumi S,Ishikawa Y,Aburatani H,Kikuchi T,Miyazono K,Koinuma D

    更新日期:2020-02-01 00:00:00

  • Pharmacologic inhibition of Akt in combination with chemotherapeutic agents effectively induces apoptosis in ovarian and endometrial cancer cell lines.

    abstract::The PI3K/Akt signaling pathway, the most frequently altered signaling system in human cancer, is a crucial inducer of dysregulated proliferation and neoplastic processes; however, few therapeutic strategies using PI3K/Akt inhibitors singly have been shown to be effective. The purpose of this paper was to underline the...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12888

    authors: Fabi F,Adam P,Parent S,Tardif L,Cadrin M,Asselin E

    更新日期:2020-12-18 00:00:00

  • The epigenetics of breast cancer.

    abstract::Epigenetic changes can be defined as stable molecular alterations of a cellular phenotype such as the gene expression profile of a cell that are heritable during somatic cell divisions (and sometimes germ line transmissions) but do not involve changes of the DNA sequence itself. Epigenetic phenomena are mediated by se...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2010.04.002

    authors: Jovanovic J,Rønneberg JA,Tost J,Kristensen V

    更新日期:2010-06-01 00:00:00

  • Essential role of HDAC6 in the regulation of PD-L1 in melanoma.

    abstract::Histone deacetylases (HDACs), originally described as histone modifiers, have more recently been demonstrated to target a variety of other proteins unrelated to the chromatin environment. In this context, our present work demonstrates that the pharmacological or genetic abrogation of HDAC6 in primary melanoma samples ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2015.12.012

    authors: M L,P PV,T K,M P,E S,J P,K V W,C L,F C,S D,M SKS,M M,A K,J PI,A S,E S,J W,E M S,A V

    更新日期:2016-05-01 00:00:00

  • Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.

    abstract::Most solid tumors, including colorectal cancers, shed cell-free DNA (ctDNA) in the blood. ctDNA can be analyzed to generate molecular profiles which capture the heterogeneity of the disease more comprehensively then tumor tissue biopsies. This approach commonly called 'liquid biopsy' can be applied to monitor response...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2015.12.005

    authors: Siravegna G,Bardelli A

    更新日期:2016-03-01 00:00:00

  • Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.

    abstract::Resistance to chemotherapy is a serious problem for the successful treatment of ovarian cancer patients but signalling pathways that contribute to this chemoinsensitivity are largely unknown. We demonstrate that the chemotherapeutic drug doxorubicin induces activation of the HER3-PI3K-AKT signalling cascade in ovarian...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2012.07.001

    authors: Bezler M,Hengstler JG,Ullrich A

    更新日期:2012-10-01 00:00:00

  • The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling.

    abstract::Triple-negative breast cancer (TNBC) liver metastasis is associated with poor prognosis and low patient survival. It occurs when tumor cells disseminate from primary tumors, circulate in blood/lymph [circulating tumor cells (CTCs)], and acquire distinct characteristics during disease progression toward the metastatic ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12533

    authors: Vishnoi M,Liu NH,Yin W,Boral D,Scamardo A,Hong D,Marchetti D

    更新日期:2019-09-01 00:00:00

  • Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells.

    abstract::Platinum-based compounds remain a well-established chemotherapy for cancer treatment despite their adverse effects which substantially restrict the therapeutic windows of the drugs. Both the cell type-specific toxicity and the clinical responsiveness of tumors have been associated with mechanisms that alter drug entry...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12648

    authors: Melnikova M,Wauer US,Mendus D,Hilger RA,Oliver TG,Mercer K,Gohlke BO,Erdmann K,Niederacher D,Neubauer H,Buderath P,Wimberger P,Kuhlmann JD,Thomale J

    更新日期:2020-04-01 00:00:00

  • Challenges in circulating tumor cell detection by the CellSearch system.

    abstract::Enumeration and characterization of circulating tumor cells (CTC) hold the promise of a real time liquid biopsy. They are however present in a large background of hematopoietic cells making their isolation technically challenging. In 2004, the CellSearch system was introduced as the first and only FDA cleared method d...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2015.12.002

    authors: Andree KC,van Dalum G,Terstappen LW

    更新日期:2016-03-01 00:00:00

  • A report from a conference jointly organised by the European Academy of Cancer Sciences and the Pontifical Academy of Sciences, The Vatican, November 16-17, 2018.

    abstract::Cancer is a massive challenge with a significant impact on society, healthcare systems, the economy and an increasing number of patients and their families. To help meet this societal challenge, the European Commission has recently proposed a mission-oriented approach to cancer in Horizon Europe, and about 60 particip...

    journal_title:Molecular oncology

    pub_type:

    doi:10.1002/1878-0261.12436

    authors: European Academy of Cancer Sciences.

    更新日期:2019-03-01 00:00:00

  • Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.

    abstract::Poly-ADP-ribose-polymerase inhibitors (PARPi) are considered to be optimal tools for specifically enhancing radiosensitivity. This effect has been shown to be replication-dependent and more profound in HR-deficient tumors. Here, we present a new mode of PARPi-mediated radiosensitization which was observed in four out ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.06.008

    authors: Kötter A,Cornils K,Borgmann K,Dahm-Daphi J,Petersen C,Dikomey E,Mansour WY

    更新日期:2014-12-01 00:00:00

  • Integrative analysis of cancer imaging readouts by networks.

    abstract::Cancer is a multifactorial and heterogeneous disease. The corresponding complexity appears at multiple levels: from the molecular and the cellular constitution to the macroscopic phenotype, and at the diagnostic and therapeutic management stages. The overall complexity can be approximated to a certain extent, e.g. cha...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2014.08.013

    authors: Dominietto M,Tsinoremas N,Capobianco E

    更新日期:2015-01-01 00:00:00

  • Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression.

    abstract::Glycosylation is the stepwise procedure of covalent attachment of oligosaccharide chains to proteins or lipids, and alterations in this process have been associated with malignant transformation. Simultaneous analysis of the expression of all glycan-related genes clearly gives the advantage of enabling a comprehensive...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2009.12.001

    authors: Potapenko IO,Haakensen VD,Lüders T,Helland A,Bukholm I,Sørlie T,Kristensen VN,Lingjaerde OC,Børresen-Dale AL

    更新日期:2010-04-01 00:00:00

  • Screening and identification of small molecule inhibitors of ErbB2-induced invasion.

    abstract::ERBB2 amplification and overexpression are strongly associated with invasive cancer with high recurrence and poor prognosis. Enhanced ErbB2 signaling induces cysteine cathepsin B and L expression leading to their higher proteolytic activity (zFRase activity), which is crucial for the invasion of ErbB2-positive breast ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.07.004

    authors: Brix DM,Rafn B,Bundgaard Clemmensen K,Andersen SH,Ambartsumian N,Jäättelä M,Kallunki T

    更新日期:2014-12-01 00:00:00

  • In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.

    abstract::The concept of polypharmacology involves the interaction of drug molecules with multiple molecular targets. It provides a unique opportunity for the repurposing of already-approved drugs to target key factors involved in human diseases. Herein, we used an in silico target prediction algorithm to investigate the mechan...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12810

    authors: Ariey-Bonnet J,Carrasco K,Le Grand M,Hoffer L,Betzi S,Feracci M,Tsvetkov P,Devred F,Collette Y,Morelli X,Ballester P,Pasquier E

    更新日期:2020-12-01 00:00:00

  • Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX® -i120 Platform: A prospective study.

    abstract::Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single-cell molecular analysis is required. We developed the ChimeraX® -i120 platform to facilitate negative enrichment, immunofluorescent labelin...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12876

    authors: Wang PX,Sun YF,Jin WX,Cheng JW,Peng HX,Xu Y,Zhou KQ,Chen LM,Huang K,Wu SY,Hu B,Zhang ZF,Guo W,Cao Y,Zhou J,Fan J,Yang XR

    更新日期:2020-12-10 00:00:00

  • Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

    abstract::Comprehensive Cancer Centres (CCCs) serve as critical drivers for improving cancer survival. In Europe, we have developed an Excellence Designation System (EDS) consisting of criteria to assess "excellence" of CCCs in translational research (bench to bedside and back), with the expectation that many European CCCs will...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2015.12.007

    authors: Rajan A,Berns A,Ringborg U,Celis J,Ponder B,Caldas C,Livingston D,Bristow RG,Hecht TT,Tursz T,van Luenen H,Bono P,Helander T,Seamon K,Smyth JF,Louvard D,Eggermont A,van Harten WH

    更新日期:2016-05-01 00:00:00

  • TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.

    abstract::cMet is a well-characterized oncogene that is the target of many drugs including small molecule and biologic pathway inhibitors, and, more recently, antibody-drug conjugates (ADCs). However, the clinical benefit from cMet-targeted therapy has been limited. We developed a novel cMet-targeted 'third-generation' ADC, TR1...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12600

    authors: Gymnopoulos M,Betancourt O,Blot V,Fujita R,Galvan D,Lieuw V,Nguyen S,Snedden J,Stewart C,Villicana J,Wojciak J,Wong E,Pardo R,Patel N,D'Hooge F,Vijayakrishnan B,Barry C,Hartley JA,Howard PW,Newman R,Coronella J

    更新日期:2020-01-01 00:00:00

  • Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer.

    abstract::Mouse models of human cancers may provide a valuable resource for the discovery of cancer biomarkers. We have developed a practical strategy for profiling specific proteins in mouse plasma using low-volume sandwich-immunoassays. We used this method to profile the levels of 14 different cytokines, acute-phase reactants...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2007.06.001

    authors: Forrester S,Hung KE,Kuick R,Kucherlapati R,Haab BB

    更新日期:2007-09-01 00:00:00

  • Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.

    abstract:PURPOSE:Lobular carcinoma in situ (LCIS) is both a risk indicator and non-obligate precursor of invasive lobular carcinoma (ILC). We sought to characterize the transcriptomic features of LCIS and ILC, with a focus on the identification of intrinsic molecular subtypes of LCIS and the changes involved in the progression ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2014.12.005

    authors: Andrade VP,Morrogh M,Qin LX,Olvera N,Giri D,Muhsen S,Sakr RA,Schizas M,Ng CK,Arroyo CD,Brogi E,Viale A,Morrow M,Reis-Filho JS,King TA

    更新日期:2015-04-01 00:00:00

  • Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

    abstract::The promise of 'personalized cancer care' with therapies toward specific molecular aberrations has potential to improve outcomes. However, there is recognized heterogeneity within any given tumor-type from patient to patient (inter-patient heterogeneity), and within an individual (intra-patient heterogeneity) as demon...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2014.09.011

    authors: Catenacci DV

    更新日期:2015-05-01 00:00:00

  • Allo-reactive T cells for the treatment of hematological malignancies.

    abstract::Several mechanisms can be responsible for control of hematological tumors by allo-reactive T cells. Following allogeneic stem cell transplantation (alloSCT) donor T cells recognizing genetic disparities presented on recipient cells and not on donor cells are main effectors of tumor control, but also of the detrimental...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.molonc.2015.10.014

    authors: Falkenburg JH,Jedema I

    更新日期:2015-12-01 00:00:00

  • A 17 gene panel for non-small-cell lung cancer prognosis identified through integrative epigenomic-transcriptomic analyses of hypoxia-induced epithelial-mesenchymal transition.

    abstract::As a critical feature of the tumor microenvironment, hypoxia is known to be a potent inducer of tumor metastasis, and it has been proposed that the initial steps in metastasis involve epithelial-mesenchymal transition (EMT). The strong correlation among hypoxia, EMT, and metastasis suggests that integrative assessment...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12491

    authors: Chen YL,Zhang Y,Wang J,Chen N,Fang W,Zhong J,Liu Y,Qin R,Yu X,Sun Z,Gao F

    更新日期:2019-07-01 00:00:00

  • Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.

    abstract::The identification of novel antimetastatic therapeutic targets is necessary for improved treatment of patients with acquired BRAF inhibitor-resistant (BRAFi-R) melanoma, in whom metastasis is a major concern. Our present study focused on the identification of such targets to explore novel antimetastatic therapeutic op...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12433

    authors: Mohapatra P,Prasad CP,Andersson T

    更新日期:2019-02-01 00:00:00

  • Translational cancer research - a coherent cancer research continuum.

    abstract::The main components of the cancer research continuum are basic/preclinical research, early and late clinical research and, after the adoption of an innovation by the healthcare or health organisations, outcomes research. Translational cancer research, defined as a coherent cancer research continuum, is mandatory to ad...

    journal_title:Molecular oncology

    pub_type: 杂志文章,评审

    doi:10.1002/1878-0261.12450

    authors: Ringborg U

    更新日期:2019-03-01 00:00:00

  • Near infrared photoimmunotherapy of B-cell lymphoma.

    abstract::Near infrared photoimmunotherapy (NIR-PIT) is a new, highly-selective cancer theranostics that employs an antibody-photo absorber conjugate (APC). NIR-PIT has successfully treated preclinical tumor models with APCs and is now in the first-in-human phase 1 clinical trial for head and neck cancer patients against EGFR. ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2016.07.010

    authors: Nagaya T,Nakamura Y,Sato K,Harada T,Choyke PL,Kobayashi H

    更新日期:2016-11-01 00:00:00

  • Tackling the cancer burden: the economic impact of primary prevention policies.

    abstract::Cancer is a noncommunicable disease (NCD) with increasing incidence and therefore constitutes a major public health issue. To reduce the health and economic burden of cancer, policy-makers across the world have implemented a range of preventative interventions targeting risk factors with a known link to the disease. I...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12812

    authors: Cheatley J,Aldea A,Lerouge A,Devaux M,Vuik S,Cecchini M

    更新日期:2020-10-05 00:00:00

  • SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma.

    abstract::In our previous study, we identified 1241 loci with somatic copy number alterations in human hepatocellular carcinoma (HCC) using Affymetrix SNP 6.0 arrays, and a putative cancer gene SERPINA5 was uncovered in a novel chromosomal region with recurrent copy number loss at 14q31.1-32.13. The SERPINA5 was reported to be ...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1016/j.molonc.2013.12.003

    authors: Jing Y,Jia D,Wong CM,Oi-Lin Ng I,Zhang Z,Liu L,Wang Q,Zhao F,Li J,Yao M,Wu X,He X

    更新日期:2014-03-01 00:00:00

  • Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.

    abstract::Chimeric inhibitors, which merge two drug pharmacophores in a single molecule have become a prominent approach for the design of novel anticancer compounds. Here, we examined animacroxam, which combines histone deacetylase (HDAC) inhibitory and cytoskeleton-interfering pharmacophores, in testicular germ cell tumors (T...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12582

    authors: Steinemann G,Dittmer A,Schmidt J,Josuttis D,Fähling M,Biersack B,Beindorff N,Jolante Koziolek E,Schobert R,Brenner W,Müller T,Nitzsche B,Höpfner M

    更新日期:2019-12-01 00:00:00

  • TRPM4 is highly expressed in human colorectal tumor buds and contributes to proliferation, cell cycle, and invasion of colorectal cancer cells.

    abstract::Transient receptor potential melastatin-4 channel (TRPM4) dysregulation contributes to heart conditions, immune diseases, and cervical and prostate cancer. Up to now, the involvement of TRPM4 in colorectal cancer (CRC) pathophysiology remains unknown. Here, we investigated tumor tissue microarrays from 379 CRC patient...

    journal_title:Molecular oncology

    pub_type: 杂志文章

    doi:10.1002/1878-0261.12566

    authors: Kappel S,Stokłosa P,Hauert B,Ross-Kaschitza D,Borgström A,Baur R,Galván JA,Zlobec I,Peinelt C

    更新日期:2019-11-01 00:00:00